论文部分内容阅读
目的:探讨凝血与纤溶功能变化在2型糖尿病微血管病变中的临床意义。方法:采用发色底物法测定正常对照组(30例)、无微血管病变组(62例)、微血管病变组(65例)纤溶酶原激活物抑制物-1(PAI-1)活性,采用免疫浊度法测定分组纤维蛋白原(FIB)水平,比较3组PAI-1及FIB水平。结果:糖尿病微血管病变组血浆PAI-1和FIB水平明显高于无微血管病变组及正常对照组(P<0.01),且糖尿病无微血管病变组血浆PAI-1和FIB水平高于正常对照组(P<0.05)。结论:2型糖尿病患者存在血液的高凝及低纤溶状态,在发生2型糖尿病微血管病变后更为明显,检测2型糖尿病患者血浆中PAI-1和FIB水平对糖尿病微血管病变的预防和治疗具有一定的临床意义。
Objective: To investigate the clinical significance of changes in coagulation and fibrinolysis in type 2 diabetic microangiopathy. Methods: The chromogenic substrate method was used to determine the activity of plasminogen activator inhibitor-1 (PAI-1) in normal control group (n = 30), non-microvascular group (n = 62), microangiopathy group Grouping fibrinogen (FIB) levels were measured by immunoturbidimetry, PAI-1 and FIB levels were compared between the three groups. Results: The levels of plasma PAI-1 and FIB in diabetic microangiopathy group were significantly higher than those in non-microvascular group and normal control group (P <0.01), and the levels of plasma PAI-1 and FIB in diabetic microangiopathy group were higher than those in normal control group <0.05). CONCLUSION: Hypercoagulability and fibrinolytic status of blood in patients with type 2 diabetes mellitus are more obvious after the occurrence of type 2 diabetes mellitus microangiopathy. The levels of PAI-1 and FIB in the plasma of patients with type 2 diabetes mellitus can prevent and treat diabetic microangiopathy Has some clinical significance.